Funder: National Institutes of Health (NIH)

Due Dates: February 5, 2025 (New) | March 5, 2025 (Renewal/Resubmission/Revision) | May 7, 2025 (AIDS) | June 5, 2025 (New) | July 5, 2025 (Renewal/Resubmission/Revision) | September 7, 2025 (AIDS) | October 5, 2025 (New) | November 5, 2025 (Renewal/Resubmission/Revision)

Funding Amounts: Budgets are not limited but must reflect actual project needs; project periods up to 5 years.

Summary: Supports preclinical development of novel PET and SPECT radioligands for brain imaging in animal models to aid drug discovery and pathophysiological studies of CNS disorders, including pilot or clinical feasibility evaluations.

Key Information: Clinical trials are not allowed under this FOA; human studies should apply to companion FOA PAR-23-164. Applications must include a biological collaborator or advisor and a data management and sharing plan.